Marker Therapeutics Inc (MRKR)

[Rkmatters]

Also, we haven't seen the extent of the data. Considering they're suggesting that recurrence is held off, is merely the tip. The degree to PFS will be revealed just how much so within a scientific abstract and not a press release; and over time, could continue to get better. Folks who understand what the findings mean, particularly the study design of when they monitor for immune activity (they evaluate months and years later), will be able to see that it means an approval if PFS and thus OS results can be repeated on a large scale.

And then there's Fast Track. :)
I believe this qualifies for Orphan designation as well.

Multiple ph II next. :)